Postoperative Delirium Risk During Regional Anesthesia

Abstract

Postoperative delirium (POD) is a frequent and severe complication in surgical patients, particularly among the elderly and those with preexisting comorbidities. While regional anesthesia is commonly perceived as a safer alternative to general anesthesia, emerging evidence suggests that the risk of POD persists, necessitating a comprehensive understanding of its epidemiology, pathophysiology, and clinical management. This review synthesizes current literature, highlights relevant risk factors, elucidates mechanisms, and discusses diagnostic and therapeutic strategies to inform clinical practice and improve patient outcomes in the perioperative setting.

Introduction

Delirium is an acute neuropsychiatric syndrome characterized by disturbances in attention, awareness, and cognition. It is a leading postoperative complication, associated with prolonged hospital stays, increased morbidity and mortality, and higher healthcare costs. While regional anesthesia (RA) is traditionally viewed as a method to reduce anesthesia-related neurocognitive risks, recent studies have indicated that the incidence of postoperative delirium remains significant in patients undergoing RA, especially in those at high risk. This article aims to provide a comprehensive overview of POD risk during regional anesthesia, integrating clinical research, pathophysiological insights, and evidence-based recommendations to enhance perioperative care.

Epidemiology / Disease Burden

POD affects an estimated 10–50% of elderly surgical patients, with variation depending on surgical type, patient demographics, and assessment methods. In the context of regional anesthesia, the reported incidence is generally lower than with general anesthesia but remains clinically important, especially in orthopedic, vascular, and major abdominal procedures. According to recent multicenter cohort studies, the incidence of POD following RA ranges from 5% to 15% in the general surgical population and may exceed 25% in high-risk groups, such as those with preexisting cognitive impairment or severe systemic illness. POD is consistently linked to adverse outcomes, including prolonged hospitalization, increased rates of institutionalization, and greater long-term cognitive decline.

Pathophysiology

The pathogenesis of postoperative delirium is multifactorial and incompletely understood, involving an interplay of neuroinflammation, neurotransmitter dysregulation, impaired cerebral autoregulation, and perioperative stress responses. Regional anesthesia may influence these mechanisms by reducing systemic inflammatory responses and minimizing exposure to volatile anesthetics; however, it does not fully eliminate delirium risk. Factors such as intraoperative hypotension, hypoxia, and altered pharmacodynamics of sedatives or adjunct drugs used during RA can disrupt cerebral homeostasis. Additionally, pain, sleep disturbances, and metabolic derangements in the postoperative period can exacerbate neural vulnerability, leading to the onset of delirium.

Risk Factors

Risk factors for POD during RA mirror those identified in the broader perioperative literature. Key predisposing factors include advanced age, preexisting cognitive impairment, sensory deficits (vision or hearing loss), multiple comorbidities, frailty, and polypharmacy. Acute precipitants such as infection, electrolyte imbalances, hypoxemia, and high perioperative pain levels further increase risk. Specific to RA, the use of sedative adjuvants (e.g., midazolam or propofol), inadequate pain control, and prolonged block duration may also contribute. Recent evidence highlights the cumulative effect of multiple risk factors, underscoring the need for comprehensive preoperative assessment and individualized risk stratification.

Clinical Features

POD typically manifests within 24–72 hours postoperatively and is characterized by fluctuating disturbances in attention, disorganized thinking, altered levels of consciousness, and perceptual abnormalities. Hyperactive, hypoactive, and mixed subtypes are recognized, with hypoactive delirium frequently underdiagnosed due to its subtle presentation. In patients under RA, delirium symptoms may be masked by residual sedation or analgesia, complicating timely recognition. Early identification is critical, as delayed diagnosis is associated with poorer outcomes and increased risk of persistent cognitive impairment.

Diagnosis

Diagnosis of POD relies on clinical assessment, utilizing standardized tools such as the Confusion Assessment Method (CAM), CAM-ICU, and the 4AT score. These instruments evaluate core features including acute onset, fluctuating course, inattention, disorganized thinking, and altered consciousness. In the context of RA, regular monitoring and documentation of mental status are essential, particularly in high-risk surgical populations. Differential diagnosis includes pain, medication effects, metabolic disturbances, and preexisting psychiatric conditions, necessitating a thorough evaluation to exclude reversible or alternative causes.

Treatment & Management

Management of POD is multifaceted, prioritizing non-pharmacological interventions aimed at reducing delirium duration and severity. Key strategies include early mobilization, orientation protocols, sleep hygiene, sensory aid provision, pain optimization, and minimization of psychoactive medications. Treatable contributors—such as infection, hypoxia, and electrolyte imbalances—should be rapidly identified and corrected. Pharmacological therapy is reserved for severe agitation or risk of harm, with low-dose antipsychotics (e.g., haloperidol) considered as a last resort. In RA patients, careful titration of intraoperative sedation, vigilant postoperative monitoring, and multidisciplinary involvement are crucial for effective prevention and management.

Recent Advances / Emerging Therapies

Recent research has focused on perioperative neuroprotection, multimodal analgesia, and tailored anesthesia protocols to mitigate POD risk. Dexmedetomidine, an α2-adrenergic agonist, has shown promise in reducing delirium incidence when used as a sedative adjunct during RA, owing to its minimal respiratory depression and neuroprotective effects. Enhanced Recovery After Surgery (ERAS) pathways, incorporating early mobilization, opioid-sparing pain management, and standardized delirium screening, have demonstrated efficacy in reducing POD rates. Ongoing clinical trials are evaluating the role of anti-inflammatory agents, cognitive prehabilitation, and advanced monitoring techniques for early delirium detection and prevention.

Guideline Recommendations

International guidelines from societies such as the American Geriatrics Society and the European Society of Anaesthesiology emphasize routine risk assessment for delirium, the use of validated screening tools, and the implementation of non-pharmacological prevention strategies. For patients undergoing RA, recommendations include minimizing benzodiazepine use, optimizing perioperative pain control, maintaining hemodynamic stability, and early identification of cognitive changes. Multidisciplinary perioperative care teams, including anesthesiologists, surgeons, nurses, and geriatricians, play a pivotal role in guideline adherence and improved patient outcomes.

Conclusion

Postoperative delirium remains a significant risk during regional anesthesia, particularly in vulnerable populations. While RA offers certain neurocognitive advantages over general anesthesia, it does not fully obviate the risk of delirium. Clinicians must maintain a high index of suspicion, implement evidence-based risk mitigation strategies, and engage in multidisciplinary collaboration to optimize perioperative neurocognitive outcomes. Continued research into pathophysiology, early detection, and novel interventions will be essential to further reduce the burden of postoperative delirium in surgical practice.